Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Open Sesame: New Keys to Unlocking the Gate to Norovirus Infection.

Lingemann M, Taube S.

Cell Host Microbe. 2018 Oct 10;24(4):463-465. doi: 10.1016/j.chom.2018.09.018.

PMID:
30308149
2.

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration.

Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG.

J Natl Cancer Inst. 2018 Aug 1;110(8):803-811. doi: 10.1093/jnci/djy088.

3.

Norovirus, glycans and attachment.

Taube S, Mallagaray A, Peters T.

Curr Opin Virol. 2018 Aug;31:33-42. doi: 10.1016/j.coviro.2018.04.007. Epub 2018 May 11. Review. No abstract available.

PMID:
29754860
4.

Human norovirus GII.4(MI001) P dimer binds fucosylated and sialylated carbohydrates.

Wegener H, Mallagaray Á, Schöne T, Peters T, Lockhauserbäumer J, Yan H, Uetrecht C, Hansman GS, Taube S.

Glycobiology. 2017 Nov 1;27(11):1027-1037. doi: 10.1093/glycob/cwx078.

PMID:
28973640
5.

Radiation and Immunotherapy in High-grade Gliomas: Where Do We Stand?

Reznik E, Smith AW, Taube S, Mann J, Yondorf MZ, Parashar B, Wernicke AG.

Am J Clin Oncol. 2018 Feb;41(2):197-212. doi: 10.1097/COC.0000000000000406. Review.

PMID:
28906259
6.

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme.

Greer L, Pannullo SC, Smith AW, Taube S, Yondorf MZ, Parashar B, Trichter S, Nedialkova L, Sabbas A, Christos P, Wernicke AG.

Cureus. 2017 Jun 24;9(6):e1388. doi: 10.7759/cureus.1388.

7.

Clinical Outcomes of Large Brain Metastases Treated With Neurosurgical Resection and Intraoperative Cesium-131 Brachytherapy: Results of a Prospective Trial.

Wernicke AG, Hirschfeld CB, Smith AW, Taube S, Yondorf MZ, Parashar B, Nedialkova L, Kulidzhanov F, Trichter S, Sabbas A, Ramakrishna R, Pannullo S, Schwartz TH.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1059-1068. doi: 10.1016/j.ijrobp.2017.03.044. Epub 2017 Jun 10.

PMID:
28721889
8.

Surgical Technique and Clinically Relevant Resection Cavity Dynamics Following Implantation of Cesium-131 (Cs-131) Brachytherapy in Patients With Brain Metastases.

Wernicke AG, Lazow SP, Taube S, Yondorf MZ, Kovanlikaya I, Nori D, Christos P, Boockvar JA, Pannullo S, Stieg PE, Schwartz TH.

Oper Neurosurg (Hagerstown). 2016 Mar;12(1):49-60. doi: 10.1227/NEU.0000000000000986. Epub 2015 Aug 1.

9.

Prevalence of human norovirus and Clostridium difficile coinfections in adult hospitalized patients.

Stokely JN, Niendorf S, Taube S, Hoehne M, Young VB, Rogers MA, Wobus CE.

Clin Epidemiol. 2016 Jun 28;8:253-60. doi: 10.2147/CLEP.S106495. eCollection 2016.

10.

Cesium-131 brachytherapy for recurrent brain metastases: durable salvage treatment for previously irradiated metastatic disease.

Wernicke AG, Smith AW, Taube S, Yondorf MZ, Parashar B, Trichter S, Nedialkova L, Sabbas A, Christos P, Ramakrishna R, Pannullo SC, Stieg PE, Schwartz TH.

J Neurosurg. 2017 Apr;126(4):1212-1219. doi: 10.3171/2016.3.JNS152836. Epub 2016 Jun 3.

PMID:
27257835
11.

Innovative Hypofractionated Stereotactic Regimen Achieves Excellent Local Control with No Radiation Necrosis: Promising Results in the Management of Patients with Small Recurrent Inoperable GBM.

Jia A, Pannullo SC, Minkowitz S, Taube S, Chang J, Parashar B, Christos P, Wernicke AG.

Cureus. 2016 Mar 17;8(3):e536. doi: 10.7759/cureus.536.

12.

Glioblastoma: Radiation treatment margins, how small is large enough?

Wernicke AG, Smith AW, Taube S, Mehta MP.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):298-305. doi: 10.1016/j.prro.2015.12.002. Epub 2015 Dec 4. Review.

PMID:
26952812
13.

A novel reverse genetics system for human norovirus.

Taube S, Wobus CE.

Trends Microbiol. 2014 Nov;22(11):604-6. doi: 10.1016/j.tim.2014.10.001. Epub 2014 Oct 16.

14.

Osteogenic induction from marmoset embryonic stem cells cultured in feeder-dependent and feeder-independent conditions.

Trettner S, Findeisen A, Taube S, Horn PA, Sasaki E, zur Nieden NI.

Osteoporos Int. 2014 Apr;25(4):1255-66. doi: 10.1007/s00198-013-2566-4. Epub 2014 Feb 15.

PMID:
24531422
15.

Breaking a vicious cycle.

Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR.

Sci Transl Med. 2013 Jul 31;5(196):196cm6. doi: 10.1126/scitranslmed.3005950.

PMID:
23903752
16.

A mouse model for human norovirus.

Taube S, Kolawole AO, Höhne M, Wilkinson JE, Handley SA, Perry JW, Thackray LB, Akkina R, Wobus CE.

MBio. 2013 Jul 16;4(4). pii: e00450-13. doi: 10.1128/mBio.00450-13.

17.

Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR).

Weber A, Taube S, Zur Stadt U, Horstmann M, Krohn K, Bradtke J, Teigler-Schlegel A, Leiblein S, Christiansen H.

Exp Hematol Oncol. 2012 Nov 9;1(1):33. doi: 10.1186/2162-3619-1-33.

18.

Disruption of the human gut microbiota following Norovirus infection.

Nelson AM, Walk ST, Taube S, Taniuchi M, Houpt ER, Wobus CE, Young VB.

PLoS One. 2012;7(10):e48224. doi: 10.1371/journal.pone.0048224. Epub 2012 Oct 30.

19.

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Altman DG, McShane LM, Sauerbrei W, Taube SE.

PLoS Med. 2012;9(5):e1001216. doi: 10.1371/journal.pmed.1001216. Epub 2012 May 29.

20.

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Altman DG, McShane LM, Sauerbrei W, Taube SE.

BMC Med. 2012 May 29;10:51. doi: 10.1186/1741-7015-10-51.

21.

Challenges in drug and biomarker co-development.

Taube SE, Lively T.

Recent Results Cancer Res. 2012;195:229-39. doi: 10.1007/978-3-642-28160-0_21. Review.

PMID:
22527510
22.

Murine noroviruses bind glycolipid and glycoprotein attachment receptors in a strain-dependent manner.

Taube S, Perry JW, McGreevy E, Yetming K, Perkins C, Henderson K, Wobus CE.

J Virol. 2012 May;86(10):5584-93. doi: 10.1128/JVI.06854-11. Epub 2012 Mar 21.

23.

Detection of human tumor cells by amplicon fusion site polymerase chain reaction (AFS-PCR).

Weber A, Taube S, Starke S, Bergmann E, Christiansen NM, Christiansen H.

J Clin Invest. 2011 Feb;121(2):545-53. doi: 10.1172/JCI44415.

24.

Transient or persistent norovirus infection does not alter the pathology of Salmonella typhimurium induced intestinal inflammation and fibrosis in mice.

Higgins PD, Johnson LA, Sauder K, Moons D, Blanco L, Taube S, Wobus CE.

Comp Immunol Microbiol Infect Dis. 2011 May;34(3):247-57. doi: 10.1016/j.cimid.2010.12.002. Epub 2011 Jan 14.

25.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC; American Society of Clinical Oncology; College of American Pathologists.

Arch Pathol Lab Med. 2010 Jul;134(7):e48-72. doi: 10.1043/1543-2165-134.7.e48. Review.

PMID:
20586616
26.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC.

Arch Pathol Lab Med. 2010 Jun;134(6):907-22. doi: 10.1043/1543-2165-134.6.907. Erratum in: Arch Pathol Lab Med. 2010 Aug;134(8):1101.

27.

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC.

J Clin Oncol. 2010 Jun 1;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529. Epub 2010 Apr 19. Review. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.

28.

Glycosphingolipids as receptors for non-enveloped viruses.

Taube S, Jiang M, Wobus CE.

Viruses. 2010 Apr;2(4):1011-49. doi: 10.3390/v2041011. Epub 2010 Apr 15.

29.

High-resolution cryo-electron microscopy structures of murine norovirus 1 and rabbit hemorrhagic disease virus reveal marked flexibility in the receptor binding domains.

Katpally U, Voss NR, Cavazza T, Taube S, Rubin JR, Young VL, Stuckey J, Ward VK, Virgin HW 4th, Wobus CE, Smith TJ.

J Virol. 2010 Jun;84(11):5836-41. doi: 10.1128/JVI.00314-10. Epub 2010 Mar 24.

30.

High-resolution x-ray structure and functional analysis of the murine norovirus 1 capsid protein protruding domain.

Taube S, Rubin JR, Katpally U, Smith TJ, Kendall A, Stuckey JA, Wobus CE.

J Virol. 2010 Jun;84(11):5695-705. doi: 10.1128/JVI.00316-10. Epub 2010 Mar 24.

31.

Biomarkers in oncology: trials and tribulations.

Taube SE.

Ann N Y Acad Sci. 2009 Oct;1180:111-8. doi: 10.1111/j.1749-6632.2009.05019.x.

PMID:
19906265
32.

A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.

Taube SE, Clark GM, Dancey JE, McShane LM, Sigman CC, Gutman SI.

J Natl Cancer Inst. 2009 Nov 4;101(21):1453-63. doi: 10.1093/jnci/djp334. Epub 2009 Oct 23.

33.

Murine norovirus-1 entry into permissive macrophages and dendritic cells is pH-independent.

Perry JW, Taube S, Wobus CE.

Virus Res. 2009 Jul;143(1):125-9. doi: 10.1016/j.virusres.2009.03.002. Epub 2009 Mar 14.

34.

Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection.

Mas Marques A, Mueller T, Welke J, Taube S, Sarrazin C, Wiese M, Halangk J, Witt H, Ahlenstiel G, Spengler U, Goebel U, Schott E, Weich V, Schlosser B, Wasmuth HE, Lammert F, Berg T, Schreier E.

Infect Genet Evol. 2009 Sep;9(5):847-52. doi: 10.1016/j.meegid.2009.05.002. Epub 2009 May 14.

PMID:
19446659
35.

Ganglioside-linked terminal sialic acid moieties on murine macrophages function as attachment receptors for murine noroviruses.

Taube S, Perry JW, Yetming K, Patel SP, Auble H, Shu L, Nawar HF, Lee CH, Connell TD, Shayman JA, Wobus CE.

J Virol. 2009 May;83(9):4092-101. doi: 10.1128/JVI.02245-08. Epub 2009 Feb 25.

36.

A functional toll-like receptor 8 variant is associated with HIV disease restriction.

Oh DY, Taube S, Hamouda O, Kücherer C, Poggensee G, Jessen H, Eckert JK, Neumann K, Storek A, Pouliot M, Borgeat P, Oh N, Schreier E, Pruss A, Hattermann K, Schumann RR.

J Infect Dis. 2008 Sep 1;198(5):701-9. doi: 10.1086/590431.

PMID:
18605904
37.

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology.

J Clin Oncol. 2007 Nov 20;25(33):5287-312. Epub 2007 Oct 22. Review.

PMID:
17954709
38.

A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection.

Schott E, Witt H, Neumann K, Taube S, Oh DY, Schreier E, Vierich S, Puhl G, Bergk A, Halangk J, Weich V, Wiedenmann B, Berg T.

J Hepatol. 2007 Aug;47(2):203-11. Epub 2007 Apr 12.

PMID:
17512627
39.

A system for sharing routine surgical pathology specimens across institutions: the Shared Pathology Informatics Network.

Drake TA, Braun J, Marchevsky A, Kohane IS, Fletcher C, Chueh H, Beckwith B, Berkowicz D, Kuo F, Zeng QT, Balis U, Holzbach A, McMurry A, Gee CE, McDonald CJ, Schadow G, Davis M, Hattab EM, Blevins L, Hook J, Becich M, Crowley RS, Taube SE, Berman J; Shared Pathology Informatics Network.

Hum Pathol. 2007 Aug;38(8):1212-25. Epub 2007 May 8.

PMID:
17490722
40.

Steering embryonic stem cell fate towards osteoblasts with downstream non-canonical wnt targets in vitro.

Taube S, Zur Nieden N.

J Stem Cells Regen Med. 2007 May 16;2(1):132. eCollection 2007. No abstract available.

PMID:
24692951
41.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology/College of American Pathologists.

Arch Pathol Lab Med. 2007;131(1):18-43. doi: 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2.

PMID:
19548375
42.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists.

J Clin Oncol. 2007 Jan 1;25(1):118-45. Epub 2006 Dec 11.

PMID:
17159189
43.

REporting recommendations for tumor MARKer prognostic studies (REMARK).

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics.

Breast Cancer Res Treat. 2006 Nov;100(2):229-35. Epub 2006 Aug 24.

PMID:
16932852
44.

Reporting recommendations for tumor marker prognostic studies (remark).

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.

Exp Oncol. 2006 Jun;28(2):99-105.

PMID:
16837898
45.

REporting recommendations for tumor MARKer prognostic studies (REMARK).

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.

Nat Clin Pract Urol. 2005 Aug;2(8):416-22.

PMID:
16482653
46.

Cancer diagnostics: decision criteria for marker utilization in the clinic.

Taube SE, Jacobson JW, Lively TG.

Am J Pharmacogenomics. 2005;5(6):357-64. Review.

PMID:
16336001
47.

Program for the Assessment of Clinical Cancer Tests (PACCT): assisting the development of tailored cancer therapy.

Taube SE, Abrams JS.

Per Med. 2005 Nov;2(4):363-369. doi: 10.2217/17410541.2.4.363.

PMID:
29788577
48.

Reporting recommendations for tumor marker prognostic studies.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.

J Clin Oncol. 2005 Dec 20;23(36):9067-72. Epub 2005 Sep 19. No abstract available.

PMID:
16172462
49.

REporting recommendations for tumor MARKer prognostic studies (REMARK).

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.

Nat Clin Pract Oncol. 2005 Aug;2(8):416-22.

PMID:
16130938
50.

REporting recommendations for tumour MARKer prognostic studies (REMARK).

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.

Br J Cancer. 2005 Aug 22;93(4):387-91.

Supplemental Content

Support Center